NCT01908725View on ClinicalTrials.gov

Lamazym Aftercare Study

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Alpha-Mannosidosis
Interventions
DRUG

Lamazym

ERT, i.v. infusions weekly

Trial Locations (1)

DK-2100

Center for Metabolic Diseases, Department of Clinical Genetics, Juliane Marie Centre, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen

All Listed Sponsors
lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT01908725 - Lamazym Aftercare Study | Biotech Hunter | Biotech Hunter